Navigation Links
ARCA biopharma to Present at JMP Securities Healthcare Focus Conference
Date:10/2/2008

saction between Nuvelo, ARCA and Dawn Acquisition Sub, Inc., the transaction's anticipated benefits, timing, progress and anticipated completion of the combined company's clinical stage and research programs, which statements are hereby identified as "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on our management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward- looking statements as a result of many factors, including, without limitation, failure of Nuvelo or ARCA's stockholders to approve the merger, the ability to complete the transaction contemplated by this communication in a timely fashion, the risk that Nuvelo's and ARCA's business operations will not be integrated successfully; the combined company's inability to further identify, develop and achieve commercial success for products and technologies; the risk that the combined company's financial resources will be insufficient to meet the combined company's business objectives; uncertainties relating to drug discovery and the regulatory approval process; clinical development processes; enrollment rates for patients in our clinical trials; changes in relationships with strategic partners and dependence upon strategic partners for the performance of critical activities under collaborative agreements; and the impact of competitive products and technological changes. These and other factors are identified and described in more detail in Nuvelo's filings with the SEC, including without limitation Nuvelo's quarterly report on Form 10-Q for the quarter ended June 30, 2008 and subsequent filings. We disclaim any intent or obligation to update these forward-looking statements.

Additional Information and Where to Find It

Nuvelo intends to file a registration statement on Form S-4, and a related proxy
'/>"/>

SOURCE ARCA biopharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Helix BioPharma Announces $11.4 Million Private Placement
2. Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
3. Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants
4. Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
5. Helix BioPharma to Present L-DOS47 Research Findings at the National Research Council of Canadas Eighth Annual General Meeting of the Genomics and Health Initiative in Saskatoon, Canada
6. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
7. Cyntellect Launches CellXpress(TM) System to Boost Productivity of Biopharmaceutical Process Development
8. China Biopharma Effects 1 for 100 Reverse Stock Split
9. Top Biopharma Company Adopts BioFortis Translational Research Software for Centralized Management and Mining of Clinical Biomarker Data
10. Therapure Biopharma Inc. opens for business with first client contracts
11. Leading Biopharmas Will Deliver Case Studies on Achieving Productivity Excellence through Engagement, Technology, Other Tools
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... “Preparative & Process Chromatography Market by ... Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, End ... to 2019” provides a detailed overview of the ... and strategies impacting the preparative and process chromatography ... the revenue and share analysis. , Full ...
(Date:12/24/2014)... 2014 SoundConnect’s ... to introduce cutting edge communication technology, provide ... of platform upgrades. This webinar series demonstrates ... in their quest to leverage web conferencing’s ... to SoundConnect’s Marketing Manager, Seanna Baumgartner, “Our ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 ... mercaptan such as its definition, classification, application ... product specification, manufacturing process, and product cost ... and applications. The analysis also covers upstream ... channels, industry development trend and proposals. In ...
(Date:12/24/2014)... CA (PRWEB) December 23, 2014 Pipette.com ... where their Twitter followers can submit their #HolidayInTheLab pictures ... and their lab mates. , For those struggling to ... mates, the Pipette.com Holiday in the Lab Contest provides ... Pipette.com Twitter followers to send pictures of their ...
Breaking Biology Technology:Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2
... Inc. today announced that data from its phase 1/2 ... be highlighted in an oral presentation at the 50th ... in San Francisco, California, on December 9, 2008. , ... of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with ...
... BioMarin Pharmaceutical,Inc. (Nasdaq: BMRN ) today announced that ... update at the Piper,Jaffray Healthcare Conference in New York City ... Interested parties may access a ... of the BioMarin website, http://www.BMRN.com . A,replay of the ...
... JOLLA, Calif., Nov. 25 TorreyPines Therapeutics, Inc.,(Nasdaq: ... from Eli Lilly & Company,a reduction in certain royalty ... sales of TorreyPines, clinical-stage compounds NGX426 and tezampanel,should either ... rate will be reduced three percentage points and the ...
Cached Biology Technology:Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting 2Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting 3BioMarin to Present at the Piper Jaffray Healthcare Conference 2TorreyPines Therapeutics Enters into Agreement to Reduce Royalty Rates and Delay Clinical Milestone Payments Due to Eli Lilly for NGX426 and Tezampanel 2
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences International ... has released a new series of digital telemetry ... toxicology researchers. M series, part of the PhysioTel™ ... the best possible physiologic data when incorporating functional ... functional endpoints to toxicology studies has evolved from ...
(Date:12/10/2014)... -- Valencell, a leader in performance biometric data sensor technology, ... its licensees for highly accurate, clinically validated biometric technology. ... from fitness and health sectors, but first responders/military and ... only as useful as the biometric data it delivers. ... long-term mass consumer adoption of wearable products," said Dr. ...
(Date:12/10/2014)... 9, 2014 CIE San Diego has launched ... the connective tissue that enhances care coordination among social ... share client-level information; earned a second $1 million grant ... serving seniors aging in community and; will be recognized ... 11 th 4-6p. CIE San Diego ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4
... "Net energy is a (mostly) irrelevant, misleading and dangerous ... Bioresources and Biorefining (Biofpr) in the latest issue ... a metric by which some scientists attempt to assess ... fossil fuel but recent debate in Biofpr shows that ...
... NASCAR, competitors and fans know that speed is only part ... elements like aerodynamic drafting, which makes it easier to follow ... -- is also critical. But in some cases, drafting ... experiences reduced drag, while the followers encounter more resistance -- ...
... University scientists concerned about lethal mold infections have found a ... gene, called srbA, allows molds to thrive during infections even ... author of a paper published in the Nov. 7 issue ... the mold becomes much more vulnerable to lack of oxygen ...
Cached Biology News:Scientific community called upon to resolve debate on 'net energy' once and for all 2Following the leader can be a drag, according to student's research on flapping flags 2Montana State University researchers find gene that regulates mold's resistance to drugs 2
Mouse monoclonal [B314.1 (MAC 387)] to Macrophage L1 protein Calprotectin (rating: ****) ( Abpromise for all tested applications)....
MOUSE ANTI HUMAN CYTOKERATIN 1-8...
Request Info...
... Polyoxyethylene Lauryl Ether 30% ... Kathon Preservative. Surfactant. Clear ... immunohistochemistry is 1 mL ... solution added to 400 ...
Biology Products: